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PROFORMA 
 
 
 
 
CONSENT FORM 
 
 
  
PROFORMA 
 
PATIENT DETAILS 
NAME : 
IP NO : 
SEX : 
AGE: days 
DOB: 
GESTATIONAL  AGE: 
BIRTH WEIGHT: 
CHIEF COMPLAINTS: 
DIAGNOSIS: 
OUTCOME OF HOSPITALIZATION: Survived [ ], Died [ ], Unknown [ ] 
MOTHER’S DETAILS 
NAME : 
AGE : 
BLOOD TYPE: 
TYPE OF DELIVERY: 
PAST MEDICATION HISTORY : 
PREVIOUS COMPLICATIONS OF PREGNANCY: 
PARA:    GRAVIDA: 
 
 
 
 
 
  
PRESENCE OF ANY OF THE FOLLOWING :     Y/N 
 Prematurity ˂ 38 weeks                       [   ] 
 Low birth weight            [   ] 
 History of hyperbilirubinemia            [   ] 
 ABO/ Rh incompatibility             [   ] 
 Non optimal feeding             [   ] 
 Central hematocrit more than 65%          [   ] 
 Presence of signs of underlying illness like 
     Vomiting/lethargy/poor feeding/temperature instability/apnea.                  [   ]  
 Jaundice visible on the first day of life         [   ] 
 Newborn's trunk is distinctly yellow stained 
  with yellow tinge of palms and soles.          [   ] 
 Geographic prevalence of G-6PD deficiency          [   ] 
 Primipara mother            [   ] 
 Reduced sucking            [   ] 
 Fever             [   ] 
 Other infections eg septicemia, UTI          [   ] 
 Diarrhoea             [   ]  
 
 
 
 
 
 
 
  
DAY 1 
General physical examination: 
Wt:        Icterus:  
Color:         Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :        TWC:   
Platelet count:       CRP:    
Blood culture:  
Serum Bilurubin : 
 Total :  
 Direct: 
Treatment: 
 
 
DAY 7 
General physical examination: 
Wt:        Icterus:                  
Color:                    Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :        TWC:    
Platelet count:       CRP:    
Blood culture: 
Serum Bilurubin : 
 Total :  
 Direct: 
 
Treatment : 
 
DAY 14 
General physical examination: 
Wt:        Icterus:                  
Color:                    Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :        TWC:    
Platelet count:       CRP:    
Blood culture: 
 Serum Bilurubin : 
 Total :  
 Direct: 
 
Treatment : 
 
 
OTHER  INFORMATION: 
 
INFORMED CONSENT 
 
Participant written informed consent 
 I understand that my participation is voluntary and that I may withdraw from this 
study at any time without giving any reason or to decline to answer any particular question in 
the study. I consent the members of the study to have access to my response and to publish 
the result, provided my identity is not revealed. I voluntarily agree to participate in the study. 
 
 
 
               Participant signature with date 
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INTRODUCTION 
RETROSPECTIVE STUDIES 
 Retrospective studies are conceived after some people have already developed the 
outcomes. The investigations find the subjects and begin collect information about them after 
outcomes have already occurred. These studies are very efficient for studying rare or unusual 
exposure, but there are many potential problems. Sometimes exposure status is not clear 
when its not necessary to go back, in time and use whatever data is available, especially 
because the data being used was not designed to answer a health question. 
 A cohort is identified and classified as to exposure to the risk factor at some date in 
the past and followed up to the present to determine incidence rate. This is called a 
retrospective cohort studies/ historical prospective study prospective study of past data.  
  Retrospective study is an epidemiological study in which participating individuals are 
classified as either having some outcomes (cases) or lacking (control); the outcome may be a 
specific disease, and the person histories are examined for specific factors that might be 
associated with the outcomes. Cases and controls are often matched with respect to certain 
demographic or other variables but need not be.[1] 
ADVANTAGES 
Retrospective cohort studies exhibit the benefits of cohort studies and have distinct 
advantages relative to prospective ones: 
• They are conducted on a smaller scale.  
• They typically require less time to complete.  
• They are generally less expensive, because resources are mainly devoted to collecting 
data.  
• They are better for analyzing multiple outcomes.  
• In a medical context, they can potentially address rare diseases, which would necessitate 
extremely large cohorts in prospective studies.  
Retrospective studies are especially helpful in addressing diseases of low incidence, since 
affected people have already been identified so. The fact that retrospective studies are 
generally less expensive than prospective studies may be another key benefit. [2] 
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DISADVANTAGES 
Certain important statistics cannot be measured. Large bias may be introduced both in the 
selection of control and in recalls of past exposure to risk factors. 
DRUG UTILIZATION STUDY 
Drug utilization study can be targeted towards any of the following links in the drug 
use chain: 
• The systems and structures are surrounding drug use  
E.g: How drugs are ordered, delivered and administrated in a hospital 
or health care facility. 
• The processes of drug use 
E.g: What drugs are used and how they are used and doses, their use 
comply with the relevant criteria, guidelines or restriction. 
• The outcomes of drug use. 
           E.g: Efficacy, Adverse drug reactions and the use of resources such as 
drugs, lab tests, Hospital beds, or procedures.[3] 
CROSS-SECTIONAL STUDIES 
 Cross sectional data provide a snap shot of drug use at a particular time (e.g – over a 
year a month or a day). Used for making comparison with similar data collected over the 
same period in a different country, health facility or ward and could be drug, problem, 
indication, prescriber or patient based. It can be carried out before and after an educational or 
other intervention. Studies can measure drug use, or can be criteria based to assess drug use 
in relation to guidelines or restrictions. 
LONGITUDINAL STUDIES 
 It’s about the trend in drug use. Drug based longitudinal data can be on total drug use 
as obtained through a claims data base or the data may be based on a statistically valid 
sample of pharmacies or medical practitioners. It can be obtained by repeated cross sectional 
studies. Data collection is continuous, but the practitioner surveyed therefore the patients are 
continually changing. It gives information about over all trends, but not about prescribing 
trends for individual practitioners or practices. 
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CONTINUOUS LONGITUDINAL STUDIES 
 Here, data at the individual practitioners and patient level can be obtained. Claim data 
base are often able to follow individuals patients unique identifier. Data provide information 
about concordance with treatment based on the period between prescriptions co-prescribing, 
duration of treatment etc.. These data bases are very powerful and can address a range of 
issue including reasons changes in therapy, ADR and health outcomes. 
NEONATAL JAUNDICE 
Neonatal jaundice is a yellowish discoloration of the white part of the eyes and skin in 
a newborn baby due to high bilirubin levels. Other symptoms may include excess sleepiness 
or poor feeding. Complications may include seizures, cerebral palsy, or kernicterus.[4]  
In many cases there is no specific underlying disorder (physiologic). In other cases it 
results from red blood cell breakdown, liver disease, infection, hypothyroidism, or metabolic 
disorders (pathologic). A bilirubin level more than 34 μmol/l (2 mg/dL) may be 
visible. Concerns, in otherwise healthy babies, occur when levels are greater than 308 μmol/L 
(18 mg/dL), jaundice is noticed in the first day of life, there is a rapid rise in levels, jaundice 
lasts more than two weeks, or the baby appears unwell. In those with concerning findings 
further investigations to determine the underlying cause are recommended.  
 
INTRODUCTION 
 
THE ERODE COLLEGE OF PHARMACY  4 
 
The need for treatment depends on bilirubin levels, the age of the child, and the 
underlying cause. Treatments may include more frequent feeding, phototherapy, 
or transfusions. In those who are born early more aggressive treatment tends to be 
required. Physiologic jaundice generally lasts less than seven days. The condition affecting 
over half of babies in the first week of life Of babies that are born early about 80% are 
affected.[2]  
TYPES 
 1. Physiological jaundice [5] 
• Appears after 24 houres. 
• Maximum intensity by 4th – 5th  day interm and 7th day in preterm. 
• TSB level within normal centiles for age in hours 
• Clinically not detectable after 14 days. 
• Disappear without any treatment. 
 2. Pathological jaundice[6] 
• Apeares within 24 houres of age. 
• Increase of bilirubin >5mg / dl/day or at a rate of >0.2 mg / dl /hr. 
• Serum bilirubin >95 percentile for age in hrs based on normogram. 
• Jaundice persisting after 14 days in full term babies. 
• Stool clay, white colored and urine staining clothes yellow. 
• Direct bilirubin >2mg / dl or > 20 % of TSB. 
 
EPIDIMIOLOGY 
United States data 
An estimated 50% of term and 80% of preterm infants develop jaundice, typically 2-4 
days afer birth [9].  Neonatal hyperbilirubinemia is extremely common because almost every 
newborn develops an unconjugated serum bilirubin level of more than 30 µmol/L (1.8 
mg/dL) during the first week of life. Incidence figures are difficult to compare because 
authors of different studies do not use the same definitions for significant neonatal 
hyperbilirubinemia or jaundice. In addition, identification of infants to be tested depends on 
visual recognition of jaundice by health care providers, which varies widely and depends both 
on observer attention and on infant characteristics such as race and gestational age [10]. 
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With the above caveats, epidemiologic studies provide a frame of reference for 
estimated incidence. In 1986, Maisels and Gifford reported 6.1% of infants with serum 
bilirubin levels of more than 220 µmol/L (12.9 mg/dL)[11]. In a 2003 study in the United 
States, 4.3% of 47,801 infants had total serum bilirubin levels in a range in which 
phototherapy was recommended by the 1994 American Academy of Pediatrics (AAP) 
guidelines, and 2.9% had values in a range in which the 1994 AAP guidelines suggest 
considering phototherapy[12].  In some LMICs, the incidence of severe neonatal jaundice may 
be as much as 100 times higher than in higher-income countries [13]. 
International data 
Incidence varies with ethnicity and geography. Incidence is higher in East Asians and 
American Indians and lower in Africans. Greeks living in Greece have a higher incidence 
than those of Greek descent living outside of Greece. 
Incidence is higher in populations living at high altitudes. In 1984, Moore et al 
reported 32.7% of infants with serum bilirubin levels of more than 205 µmol/L (12 mg/dL) at 
3100 m of altitude [14]. 
A study from Turkey reported significant jaundice in 10.5% of term infants and in 
25.3% of near-term infants [15]. Significant jaundice was defined according to gestational and 
postnatal age and leveled off at 14 mg/dL (240 µmol/L) at 4 days in preterm infants and 17 
mg/dL (290 µmol/L) in the term infants. Severe neonatal jaundice is 100-fold more frequent 
in Nigeria than in industrialized countries [13]. In Denmark, 24 in 100.000 infants met 
exchange transfusion criteria, while 9 in 100.000 developed acute bilirubin encephalopathy 
[16]. 
Studies seem to suggest that some of the ethnic variability in the incidence and 
severity of neonatal jaundice may be related to differences in the distribution of the genetic 
variants in bilirubin metabolism discussed above [17,18]. 
Race-related demographics 
The incidence of neonatal jaundice is increased in infants of East Asian, American 
Indian, and Greek descent, although the latter appears to apply only to infants born in Greece 
and thus may be environmental rather than ethnic in origin. African infants are affected less 
often than non-African infants. For this reason, significant jaundice in an African infant 
merits a closer evaluation of possible causes, including G-6-PD deficiency. In 1985, Linn et 
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al reported on a series in which 49% of East Asian, 20% of white, and 12% of black infants 
had serum bilirubin levels of more than 170 µmol/L (10 mg/dL)[19]. 
The possible impact of genetic polymorphisms on ethnic variation in incidence and 
severity should be recognized. Thus, in a study of Taiwanese infants, Huang et al reported 
that neonates who carry the 211 and 388 variants in the UGT1A1 and OATP2 genes and who 
are breastfed are at particularly high risk for severe hyperbilirubinemia[17]. 
Sex- and age-related demographics 
Risk of developing significant neonatal jaundice is higher in male infants. This does 
not appear to be related to bilirubin production rates, which are similar to those in female 
infants. 
The risk of significant neonatal jaundice is inversely proportional to gestational age. 
prognosis 
Prognosis is excellent if the patient receives treatment according to accepted 
guidelines. Brain damage due to kernicterus remains a true risk, and the apparent increased 
incidence of kernicterus in recent years may be due to the misconception that jaundice in the 
healthy full-term infant is not dangerous and can be disregarded. 
Mortality/morbidity 
Kernicterus is a complication of neonatal jaundice. The incidence of kernicterus in 
North America and Europe ranges from 0.4-2.7 cases per 100,000 births[20]. Death from 
physiologic neonatal jaundice per se should not occur. Death from kernicterus may occur, 
particularly in countries with less developed medical care systems. In one small study from 
rural Nigeria, 31% of infants with clinical jaundice tested had G-6-PD deficiency, and 36% of 
the infants with G-6-PD deficiency died with presumed kernicterus compared with only 3% 
of the infants with a normal G-6-PD screening test result[21]. 
ETIOLOGY 
Physiologic jaundice is caused by a combination of increased bilirubin production 
secondary to accelerated destruction of erythrocytes, decreased excretory capacity secondary 
to low levels of ligandin in hepatocytes, and low activity of the bilirubin-conjugating enzyme 
uridine diphosphoglucuronyltransferase (UDPGT). 
Pathologic neonatal jaundice occurs when additional factors accompany the basic 
mechanisms described above. Examples include immune or nonimmune hemolytic 
anemia, polycythemia, and the presence of bruising or other extravasation of blood. 
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Decreased clearance of bilirubin may play a role in breast feeding jaundice, breast 
milk jaundice, and in several metabolic and endocrine disorders. 
Risk factors include the following: 
• Race: Incidence is higher in East Asians and American Indians and is lower in 
Africans/African Americans. 
• Geography: Incidence is higher in populations living at high altitudes. Greeks living in 
Greece appear to have a higher incidence than those living outside of Greece. 
• Genetics and familial risk: Incidence is higher in infants with siblings who had 
significant neonatal jaundice and particularly in infants whose older siblings were 
treated for neonatal jaundice. Incidence is also higher in infants with 
mutations/polymorphisms in the genes that code for enzymes and proteins involved in 
bilirubin metabolism, and in infants with homozygous or heterozygous glucose-6-
phosphatase dehydrogenase (G-6-PD) deficiency and other hereditary hemolytic 
anemias. Combinations of such genetic variants appear to exacerbate neonatal 
jaundice[17,22,23,24].  
• Nutrition: Incidence is higher in infants who are breastfed or who receive inadequate 
nutrition. The mechanism for this phenomenon may not be fully understood. However, 
when inadequate feeding volume is involved, increased enterohepatic circulation of 
bilirubin probably contributes to prolonged jaundice. Recent data have shown that 
breast milk jaundice correlates with higher levels of epidermal growth factor, both in 
breast milk and in infants' serum[25].Data suggest that the difference between breastfed 
and formula-fed infants may be less pronounced with some modern formulas. However, 
formulas containing protein hydrolysates have been shown to promote bilirubin 
excretion. 
• Maternal factors: Infants of mothers with diabetes have higher incidence. Use of some 
drugs may increase the incidence, whereas others decrease the incidence. Some herbal 
remedies taken by the lactating mother may apparently exacerbate jaundice in the 
infant. 
• Birthweight and gestational age: Incidence is higher in premature infants and in infants 
with low birthweight. 
• Congenital infection 
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PATHOPHYSIOLOGY 
 
Bile formation 
Bile is a bitter yellow, blue and green fluid produced by hepatocytes in the liver, 
draining through the many bile ducts that penetrate the liver.During this process, the 
epithelial cells add a watery solution that is rich in bicarbonates and that dilutes and increases 
alkalinity of the solution. Bile then flows into the common hepatic duct, which joins with the 
cystic duct from the gall bladder to form the common bile duct. The common bile duct in turn 
joins with the pancreatic duct to empty into the duodenum  
 
 
 
 
 
Constituents of bile: 
Bile has various components, some of which are produced by 
hepatocytes in the liver. The main components include  
❖ Water. 
❖ Cholesterol. 
❖ Bile pigments. 
❖ Bile acids (glycocholic and taurocholic acid). 
❖ Phospholipids (mainly lecithin). 
❖ Bicarbonate and acids. 
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Bilirubin Production 
Bilirubin is a product of the breakdown of the heme portion of hemoglobin that occurs 
when red blood cells are destroyed. Normally, bilirubin is excreted through the body after 
passing through the liver,spleen, kidneys and the gastrointestinal tract. 
 
TYPES OF BILIRUBIN 
There are two types of bilirubin circulating in the blood stream, unconjugated and 
conjugated. 
1.Unconjugated bilirubin (or indirect bilirubin) can be found in circulating blood either 
Bound to albumin or not. It is fat-soluble and therefore more potentially toxic since it can 
bind to the tissues. Most of the unconjugated bilirubin is bound to albumin and transported to 
the liver. There, it is converted to glucuronic acid aided by uridine diphosphate glucuronosyl 
transferase (UDGT) to produce conjugated bilirubin. Once it becomes conjugated, it is sent to 
the gut for excretion via the biliary system. The unbound, unconjugated bilirubin is most 
likely to cross the blood-brain barrier and settle in the tissues where it can cause temporary or 
permanent neurological damage. Once it settles in the brain, it is there forever. The unbound 
bilirubin is difficult to measure but it is thought that it is directly related to the amount of 
unconjugated bilirubin. 
2.Conjugated bilirubin (or direct bilirubin) is water-soluble and therefore is a more stable 
and non-toxic form. This allows it to be easily excreted from the body in urine and stool. 
Elevated levels of conjugated bilirubin may indicate evidence of liver disease. 
 
FACTORS AFFECTING BILIRUBIN METABOLISM 
Increased Production 
Any disorder which causes an increase in the number of red blood cells such as 
polycythemia, will lead to an increase in the amount of bilirubin produced as these cells 
breakdown. If there is a decreased amount of albumin available, there will be decreased 
binding capacity and conversion of indirect to direct bilirubin in the liver resulting in more 
indirect bilirubin that could potentially cross the blood-brain barrier or settle in the tissues. 
Bruising will also increase the breakdown of RBCs and increase bilirubin levels. 
 Decreased Conjugation 
Conditions such as acidosis and hypoxia can also affect the bilirubin/albumin ratio for 
binding. The presence of any type of liver disease, metabolic or enzyme disorder will also 
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affect the ability of the body to convert bilirubin to the direct form to allow for excretion. 
 Because bilirubin is changed in the gut to urobilinogen with the assistance of the 
normal intestinal flora, anything that affects normal gut function can affect the excretion of 
bilirubin from the body. We know that at birth, the infant’s gut is not fully developed so that 
prematurity and/or any disorder of the bowel, as well as antibiotic therapy, can slow the 
excretion of bilirubin. 
 
 
 
Neonatal physiologic jaundice results from simultaneous occurrence of the following two 
phenomena[17] : 
• Bilirubin production is elevated because of increased breakdown of fetal erythrocytes. 
This is the result of the shortened lifespan of fetal erythrocytes and the higher 
erythrocyte mass in neonates[26,9].  
• Hepatic excretory capacity is low both because of low concentrations of the binding 
protein ligand in in the hepatocytes and because of low activity of glucuronyl 
transferase, the enzyme responsible for binding bilirubin to glucuronic acid, thus 
making bilirubin water soluble (conjugation). 
INTRODUCTION 
 
THE ERODE COLLEGE OF PHARMACY  11 
 
Bilurubin is produced in the reticuloendothelial system as the end product of heme 
catabolism and is formed through oxidation-reduction reactions. Approximately 75% of 
bilirubin is derived from hemoglobin, but degradation of myoglobin, cytochromes, and 
catalase also contributes. In the first oxidation step, biliverdin is formed from heme through 
the action of heme oxygenase, the rate-limiting step in the process, releasing iron and carbon 
monoxide. The iron is conserved for reuse, whereas carbon monoxide is excreted through the 
lungs and can be measured in the patient's breath to quantify bilirubin production. 
Next, water-soluble biliverdin is reduced to bilirubin, which, because of the intra-
molecular hydrogen bonds, is almost insoluble in water in its most common isomeric form 
(bilirubin IXα Z,Z). Because of its hydrophobic nature, un conjugated bilirubin is transported 
in the plasma tightly bound to albumin. Binding to other proteins and erythrocytes also 
occurs, but the physiologic role is probably limited. Binding of bilirubin to albumin increases 
postnatally with age and is reduced in infants who are ill. 
The presence of endogenous and exogenous binding competitors, such as certain 
drugs, also decreases the binding affinity of albumin for bilirubin. A minute fraction of 
unconjugated bilirubin in serum is not bound to albumin. This free bilirubin is able to cross 
lipid-containing membranes, including the blood-brain barrier, leading to neurotoxicity. In 
fetal life, free bilirubin crosses the placenta, possibly by a carrier-mediated process, [27] and 
excretion of bilirubin from the fetus occurs primarily through the maternal organism. 
When it reaches the liver, bilirubin is transported into liver cells, where it binds to 
ligandin. Uptake of bilirubin into hepatocytes increases with increasing ligandin 
concentrations. Ligandin concentrations are low at birth but rapidly increase over the first few 
weeks of life. Ligandin concentrations may be increased by the administration of 
pharmacologic agents such as phenobarbital. 
Bilirubin is bound to glucuronic acid (conjugated) in the hepatocyte endoplasmic 
reticulum in a reaction catalyzed by uridine di phospho-glucuronyl transferase (UDPGT). 
Mono conjugates are formed first and predominate in the newborn. Dic-onjugates appear to 
be formed at the cell membrane and may require the presence of the UDPGT tetramer. 
Bilirubin conjugation is biologically critical because it transforms a water-insoluble 
bilirubin molecule into a water-soluble molecule. Water-solubility allows conjugated 
bilirubin to be excreted into bile. UDPGT activity is low at birth but increases to adult values 
by age 4-8 weeks. In addition, certain drugs (phenobarbital, dexa-methasone, clofibrate) can 
be administered to increase UDPGT activity. 
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Infants who have Gilbert syndrome or who are compound hetero-zygotes for the 
Gilbert promoter and structural mutations of the UDPGT1A1 coding region are at an 
increased risk of significant hyperbilirubinemia. Interactions between the Gilbert genotype 
and hemolytic anemia’s such as glucose-6-phosphatase dehydrogenase (G-6-PD) deficiency, 
hereditary spherocytosis, or ABO hemolytic disease also appear to increase the risk of severe 
neonatal jaundice. 
Further, the observation of jaundice in some infants with hypertrophic pyloric 
stenosis may also be related to a Gilbert-type variant. Genetic polymorphism for the organic 
anion transporter protein OATP-2 correlates with a 3-fold increased risk for developing 
marked neonatal jaundice. Combination of the OATP-2 gene polymorphism with a 
variant UDPGT1A1 gene further increases this risk to 22-fold. Studies also suggest that 
polymorphisms in the gene for glutathione-S-transferase (ligandin) may contribute to higher 
levels of total serum bilirubin. 
Thus, some inter individual variations in the course and severity of neonatal jaundice 
may be explained genetically [28].   As the impact of these genetic variants is more fully 
understood, development of a genetic test panel for risk of severe and/or prolonged neonatal 
jaundice may become feasible [29]. 
Once excreted into bile and transferred to the intestines, bilirubin is eventually 
reduced to colorless tetrapyrroles by microbes in the colon. However, some deconjugation 
occurs in the proximal small intestine through the action of B-glucuronidases located in the 
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brush border. This unconjugated bilirubin can be reabsorbed into the circulation, increasing 
the total plasma bilirubin pool. This cycle of uptake, conjugation, excretion, deconjugation, 
and reabsorption is termed 'enterohepatic circulation'. The process may be extensive in the 
neonate, partly because nutrient intake is limited in the first days of life, prolonging the 
intestinal transit time. 
In mother-infant dyads who are experiencing difficulties with the establishment of 
breast feeding, inadequate fluid and nutrient intake often leads to significant postnatal weight 
loss in the infant. Such infants have an increased risk of developing jaundice through 
increased enterohepatic circulation, as described above. This phenomenon is often referred to 
as breastfeeding jaundice and is different from the breast milk jaundice described below. 
Certain factors present in the breast milk of some mothers may also contribute to 
increased enterohepatic circulation of bilirubin (breast milk jaundice). Β-glucuronidase may 
play a role by uncoupling bilirubin from its binding to glucuronic acid, thus making it 
available for reabsorption. Data suggest that the risk of breast milk jaundice is significantly 
increased in infants who have genetic polymorphisms in the coding sequences of 
the UDPGT1A1[30] or OATP2 genes. Although the mechanism that causes this phenomenon is 
not yet agreed on, evidence suggests that supplementation with certain breast milk substitutes 
may reduce the degree of breast milk jaundice. 
Neonatal jaundice, although a normal transitional phenomenon in most infants, can 
occasionally become more pronounced. Blood group incompatibilities (eg, Rh, ABO) may 
increase bilirubin production through increased hemolysis. Historically, Rh iso-immunization 
was an important cause of severe jaundice, often resulting in the development of kernicterus. 
Although this condition has become relatively rare in industrialized countries following the 
use of Rh prophylaxis in Rh-negative women, Rh isoimmunization remains common in low- 
and middle-income countries (LMICs). 
Non immune hemolytic disorders (spherocytosis, G-6-PD deficiency) may also cause 
increased jaundice, and increased hemolysis appears to have been present in some of the 
infants reported to have developed kernicterus in the United States in the past 15-20 years. 
The possible interaction between such conditions and genetic variants of the Gilbert 
and UDPGT1A1 genes, as well as genetic variants of several other proteins and enzymes 
involved in bilirubin metabolism, is discussed above. More recently, 3 novel mutations in 
genes encoding either alpha or beta spectrin (SPTA1 or SPTB) were found in 3 unrelated 
neonates with non-immune hemolytic jaundice [31]. 
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These discoveries also highlight the challenges involved in the common use of the 
terms physiologic jaundice and pathologic jaundice. Although physiologic jaundice is a 
helpful concept from a didactic perspective, applying it to an actual neonate with jaundice is 
more difficult. 
Consider the following metaphor: Think of total serum bilirubin in neonatal jaundice 
as a mountain covered by a glacier. If a measurement of the height of the mountain is taken 
when standing on the summit, the amount of rock and the amount of ice that comprise this 
measurement is unclear. The same is true for many total serum bilirubin values obtained in 
neonatal jaundice. An underpinning of physiologic processes and pathological process (eg, 
Rhesus incompatibility) may clearly contribute to the measurement. However, how much of 
the measured total value comes from each of these components is unclear. Also, because 
genetic variants in bilirubin metabolism are only exceptionally pursued in the diagnostic 
work-up of infants with jaundice, their possible contribution to the measured total serum 
bilirubin is usually unknown. 
CAUSES  
In newborns, jaundice tends to develop because of two factors—the breakdown 
of fetal hemoglobin as it is replaced with adult hemoglobin and the relatively immature 
metabolic pathways of the liver, which are unable to conjugate and so excrete bilirubin as 
quickly as an adult. 
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  This causes an accumulation of bilirubin in the blood (hyperbilirubinemia), leading to 
the symptoms of jaundice. If the neonatal jaundice does not clear up with 
simple phototherapy, other causes such as biliary atresia, Progressive familial intra-hepatic 
cholestasis, bile duct paucity, Alagille syndrome, alpha 1-antitrypsin deficiency, and other 
pediatric liver diseases should be considered. The evaluation for these will include blood 
work and a variety of diagnostic tests. Prolonged neonatal jaundice is serious and should be 
followed up promptly. Severe neonatal jaundice may indicate the presence of other 
conditions contributing to the elevated bilirubin levels, of which there are a large variety of 
possibilities (see below). These should be detected or excluded as part of the differential 
diagnosis to prevent the development of complications.  
SIGNS AND SYMPTOMS 
The primary symptom is yellowish discoloration of the white part of the 
eyes and skin in a newborn baby. Other symptoms may include excess sleepiness or poor 
feeding.[7] A bilirubin level more than 34 μmol/l (2 mg/dL) may be visible. For the feet to be 
affected level generally must be over 255 μmol/l (15 mg/dL).[7]  
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BILIRUBIN ENCEPHALOPATHY (BILIRUBIN TOXICITY) 
Normally, hyperbilirubinemia resolves on its own as the infant processes the bilirubin 
and excretes it. However, in some infants, it can become harmful and will need treatment. If 
not detected or left untreated and levels rise too high, some of the bilirubin may cross the 
blood brain barrier and settle into brain tissue where it can cause acute bilirubin 
encephalopathy (ABE). This encephalopathy, if not detected early and treated, can develop 
into kernicterus. Kernicterus is a potentially fatal disease and results in permanent injury to 
specific parts of the brain [32].  
To help quantify the degree of ABE, the Bilirubin-Induced Neurological Dysfunction 
(BIND) score was developed. It describes three phases of worsening encephalopathy and the 
clinical signs in each phase: 
Initial phase: 
➢ lethargy, decrease in tone or activity 
Intermediate phase: 
➢ moderate stupor, irritability and variable activity 
➢ increased tone, some retrocollis/opisthotonus 
➢ minimal feeding, high-pitched cry 
Advanced phase: 
➢ deep stupor to coma, hyper-tonicity 
➢ retrocollis/opisthotonus 
➢ no feeding, shrill cry, seizures, death 
 
SCREENING STEPS 
The content of this section is based on the Ontario Ministry of Health and Long-Term 
Care (MOHTLC) Quality-Based Procedure (QBP) titled Hyperbilirubinemia in Term and 
Late Pre-Term Infants (≥ 35 weeks) (2013). The key objectives of the QBP for 
Hyperbilirubinemia are to: 
➢ ensure all newborns receive bilirubin screening between 24-72 hours of life 
(if not clinically indicated and performed earlier) 
➢ ensure infants receive systematic bilirubin monitoring as per the treatment 
graph and risk nomograms recommended by evidence-based guidelines 
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➢ utilize health care resources responsibly through avoidance of 
unnecessary/excessive testing, timely discharge, appropriate outpatient 
follow-up and minimization of preventable readmission 
➢ reduce the incidence of severe hyperbilirubinemia and acute bilirubin 
encephalopathy[33]. 
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ASSESSMENT OF JAUNDICE 
1. Physical Assessment 
• Visual assessment: Jaundice moves from head to toe, with the eyes affected last. 
Serum bilirubin (approx.) 
= 85 micromols/L - When yellow tinge first becomes visible 
= 150 micromols/L - Yellow tinge appears on trunk 
= 200 micromols/L - Yellow tinge appears on legs 
= 250 micromols/L - Eyes (sclera) are affected 
• Although visual assessment alone cannot determine the degree of jaundice, a general 
 Assessment of the extent of jaundice can be done under bright light. It is important to: 
➢ Blanch skin to determine underlying colour. 
➢ Press over a bony prominence for best results (nose, forehead). 
➢ Check sclera. 
NOTE: For dark skinned infants, the colour of the sclera, conjunctiva and oral mucosa is 
 most reliable indicator of level of jaundice[34]. 
NOTE: Petechiae may indicate underlying sepsis or haemolytic disease. 
• Level of activity: 
➢ Increasing levels of unconjugated bilirubin in the brain can lead to decreased 
levels of    Consciousness or alertness. Infants may become lethargic and 
less responsive[39]. 
• Level of hydration: 
➢ Monitor intake and output. 
➢ Adequate hydration is necessary to help maintain enough fluid to help with the 
 absorption and excretion of conjugated bilirubin once it passes through the liver. 
• Stools: 
➢ Monitor frequency, type and colour of stools (meconium versus transitional). 
➢ Unconjugated bilirubin can accumulate in stool and thus has the potential to be 
           Reabsorbed[38]. 
➢ Conjugated bilirubin can also become unconjugated in the gut and become reabsorbed     
 into the blood stream. 
2. Laboratory Assessment 
➢ Obtain serum bilirubin levels as per algorithm . 
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➢ NOTE: When bloodwork is being drawn, phototherapy should be stopped to 
prevent the sample 
➢ from being affected by the lights. The total bilirubin should be interpreted 
according to the 
➢ infant’s age in hours to determine the treatment plan and timing of reassessment. 
➢ Other blood work that may be ordered[40]. 
➢ Serum albumin - to help determine how much albumin is available for binding 
➢ CBC and differential – can help determine level of red blood cell destruction, 
haemolytic anemia, sepsis or polycythemia[42] 
➢ Direct Antiglobulin Test (DAT) - to look for presence of maternal antibodies in 
infant’s serum. NOTE: Indirect Antibody Test (IAT) is done on maternal serum 
antenatally 
➢ G6PD (glucose-6-phosphate dehydrogenase) – helps maintain RBC wall integrity; 
a deficiency indicates enzyme deficiency and a possible metabolic reason for 
jaundice.   
 
THERAPEUTIC OPTIONS  
1. Phototherapy  
Phototherapy (PTx) remains the mainstay of treating hyperbilirubinemia in neonates. 
PTx is highly effective and carries an excellent safety track record of over 50 years. It acts by 
converting insoluble bilirubin (unconjugated) into soluble isomers that can be excreted in 
urine and feces. Many review articles have provided detailed discussion on phototherapy 
related issues. The bilirubin molecule isomerizes to harmless forms under blue-green light 
(460 to 490 nm); and the light sources having high irradiance in this particular wavelength 
range are more effective than the others[42].  
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Types of phototherapy lights  
The phototherapy units available in the market have a variety of light sources that 
include florescent lamps of different colors (cool white, blue, green, blue-green or turquoise) 
and shapes (straight or U-shaped commonly referred as compact florescent lamps ie CFL), 
halogen bulbs, high intensity light emitting diodes (LED) and fibro-optic light sources. With 
the easy availability and low cost in India, CFL phototherapy is being most commonly used 
device. Often, CFL devices have four blue and two white (for examination purpose) CFLs but 
this combination can be replaced with 6 blue CFLs in order to increase the irradiance output. 
In last couple of years, blue LED is making inroads in neonatal practice and has been found 
to at least equally effective. LED has advantage of long life (up to 50,000 hrs) and is capable 
of delivering higher irradiance than CFL lamps. Fiber-optic units can be used to provide 
undersurface phototherapy in conjugation with overhead CFL/LED unit to enhance the 
efficacy of PTx but as a standalone source, fiber-optic unit is lesser effective than CFL/LED 
unit. It is important that a plastic cover or shield be placed before phototherapy lamps to 
avoid accidental injury to the baby in case a lamp breaks. 
  
Maximizing the efficacy of phototherapy  
The irradiance of PTx lights should be periodically measured, and a minimum level of 
30 μW/cm2 /nm in the wavelength range of 460 to 490 nm must be ensured. As the irradiance 
varies at different points on the footprint of a unit, it should be measured at several points. 
The lamps should be changed if the lamps are flickering or ends are blackened, if irradiance 
falls below the specified level or as per the recommendation of manufacturers. Expose 
maximal surface area of the baby[34,42]. Avoid blocking the lights by any equipment (say 
radiant warmer), a large diaper or eye patch, a cap or hat, tape, dressing or electrode etc. 
ensure good hydration and nutrition of the baby. Make sure that light falls on the baby 
perpendicularly if the baby is in incubator. Minimize interruption of Ptx during feeding 
sessions or procedures. 
 
 Administering phototherapy  
Make sure that ambient room temperature is optimum (250 to 280 ) to prevent 
hypothermia or hyperthermia in the baby. Remove all clothes of the baby except the diaper. 
Cover the baby’s eyes with patches, ensuring that the patches do not block the baby’s 
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nostrils. Place the naked baby under the lights in a cot or bassinet if weight is more than 2 kg 
or in an incubator or radiant warmer if the baby is small (›2kg) 
Keep the distance between baby and light 30 to 45 cm (or as per manufacturer 
recommendation). Ensure optimum breastfeeding. Baby can be taken out for breastfeeding 
sessions and the eye patch can be removed for better mother-infant interaction. However, 
minimize interruption to enhance effectiveness of phototherapy. There is no need to 
supplement or replace breast milk with any other types of feed or fluid (e.g. breast-milk 
substitute, water, sugar water, etc.) 
 
 Monitoring & stopping phototherapy  
Monitor temperature of the baby every 2 to 4 hr. Measure TSB level every 12 to 24 
hours. Discontinue PTx once two TSB values 12 hr apart fall below current age specific cut 
offs. The infant should be monitored clinically for rebound bilirubin rise within 24 hours after 
stopping phototherapy for babies with hemolytic disorders. 
 Role of sunlight  
Exposing the baby to sunlight does not help in treatment of jaundice and is associated 
with risk of sunburn and therefore should be avoided. 
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PHOTOTHERAPY PRINCIPLES 
Phototherapy acts on unconjugated bilirubin to a depth of 2 to 3 mm. Through 
photoisomerization, fat soluble molecules are reconfigured to water soluble molecules and 
are  excreted by the liver without actual conjugation[42]. 
Effectiveness of phototherapy = 
Area of skin exposed + Radiant energy + Wavelength of light used 
 
 
➢ The most effective light sources for degrading bilirubin are those that emit blue-green 
light in a relatively narrow wavelength range (425 – 490 nanometers). 
➢ When phototherapy is used, the decrease in bilirubin level is proportionately greater 
in the skin than in the serum. The infant should have as much skin as possible 
exposed to the lights. 
➢ It is possible to increase the efficacy of treatment by using multiple sources of 
phototherapy      to optimize the amount of skin exposed. 
➢ According to standards of care phototherapy is ordered as either intensive (high) or 
standard (low) intensity and expressed in nanometers of light. 
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PHOTOTHERAPY EQUIPMENT 
 
There are a variety of methods of delivering phototherapy. The method used depends 
on the equipment availability in each institution[38,44]. The following are the current 
recommended methods: 
 
➢ Phototherapy Lights: Deliver light in the narrow spectrum most effective for 
reducing bilirubin. Their effectiveness depends on the distance from the baby as 
measured by a specific light meter. 
➢ Bili Bassinet: Self-contained unit that combines a mattress area and three 
phototherapy  light units to provide phototherapy and may be used as an adjunct 
therapy to phototherapy  lights, but should not be used as the sole source of therapy. 
➢ Bili Blanket: A small fiber optic pad is placed under the infant. It can be used as an 
adjunct to overhead phototherapy lights but not as the only source of phototherapy. 
The advantage of a bili blanket is that it can remain in place for breastfeeding, 
providing continuity of therapy. 
 
POTENTIAL SIDE EFFECTS OF PHOTOTHERAPY [39] 
Altered Activity 
• Lethargy or irritability 
• Decreased eagerness to feed 
Altered Fluid Status 
• Increased peripheral blood flow 
• Increased insensible water loss with open bed or warmer 
Altered GI Function 
• Increased number and frequency of watery, greenish-brown stools 
• Decreased time for intestinal transit 
• Decreased absorption, retention of nitrogen, water, electrolytes 
Hematological Function 
• Increased rate of platelet turnover 
• Damage to circulating red blood cells with decreased potassium and increased ATP 
(energy) activity 
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Ocular Effects 
• Lack of sensory input and stimulation 
• Use of eye patches for prolonged period 
Skin Changes  
• Tanning 
• Rashes 
• Burns 
• Bronze Baby Syndrome 
Altered Thermal /Metabolic Function 
• Increased environmental and body temperature changes 
• Increased O2 consumption 
• Increased respiratory rate 
• Increased skin blood flow 
NURSING CARE 
Nursing care of the infant with hyperbilirubinemia is focused on assessment and 
management of the signs and symptoms of the disease. The main goals of treatment are to 
reverse the haemolytic process and prevent the development of bilirubin-induced 
encephalopathy. Most infants with hyperbilirubinemia will require the use of phototherapy to 
help reduce the amount of unconjugated (indirect) bilirubin. The guidelines included here 
refer to newborns receiving phototherapy[36,37]. 
 Feeding and Nutrition 
❖  Fluid intake is crucial to treatment success so this is an important factor to consider in 
caring      for an infant with jaundice. Dehydration may be associated with increased 
serum bilirubin  concentrations and intravenous (IV) therapy may be necessary to 
ensure adequate hydration. 
❖ Breastfeeding should always be strongly encouraged and supported, even when the   
infant is  receiving phototherapy. Although more frequent breastfeeding may be 
beneficial, it is important to minimize the time that intensive phototherapy is 
interrupted to 20 minutes within a 3-hour. period If possible, provide a referral to a 
Lactation Consultant for a more specific assessment of breastfeeding[44]. 
❖ Accurate recording of intake and output, including stool pattern, is necessary. If the 
infant is receiving IV therapy, usual standards of care should be followed. 
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 Skin Care and Thermoregulation 
❖ Skin plays an important role in the regulation of body temperature and serves as a 
route of       water excretion. 
❖  Skin care includes observing colour, rashes and excoriation; cleaning the skin with 
warm water,   especially the perineal area after stooling; changing position every 2 
hours. NOTE: Prompt   cleansing of perianal area after stooling is important as 
photo-oxidation of bilirubin results in   loose green caustic stools and can result in 
excoriation. 
❖ Phototherapy is most effective when the exposed skin area is maximized, so infants 
in isolettes should be exposed as much as possible; otherwise, diapers to catch 
urine and stool should be  used. 
❖ The infant’s temperature must be monitored at least every 4 hours to maintain a 
safe environment. 
 Eye Care 
❖ The infant’s eyes must be protected from the phototherapy lights to prevent retinal    
damage.  Place the pads correctly over the eyes: 
• Use the appropriate size of the eye pad or prefabricated eye protection. 
• Make sure the eyes are closed first to help prevent corneal abrasion,  
 irritation and/or   infection 
• Check frequently to make sure the eye pads remain in place and are not  
 obstructing the nares[39,43]. 
❖ Eye protection should be removed every 2 to 4 hours and eyes cleansed with 
normal saline to reduce irritation and promote eye contact, socialization and 
attachment. 
NOTE: Eye patches are not necessary if only the Bili  Blanket is being used since the infant’s 
eyes are not directly exposed to the blue lights. 
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GUIDELINES FOR INTENSIVE PHOTOTHERAPY FOR INFANTS ≥ 35 WEEKS 
 
Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation. 
Note: These guidelines are based on limited evidence and the levels shown are 
approximations. The guidelines refer to the use of intensive phototherapy which should be 
used when the TSB exceeds the line indicated for each category. Infants are designated as 
“higher risk” because of the potential negative effects of the conditions listed on albumin 
binding of bilirubin,45–47 the blood-brain barrier,48 and the susceptibility of the brain cells 
to damage by bilirubin.48“Intensive phototherapy” implies irradiance in the blue-green 
spectrum (wavelengths of approximately 430–490 nm) of at least 30 μW/cm2 per nm 
(measured at the infant’s skin directly below the center of the phototherapy unit) and 
delivered to as much of the infant’s surface area as possible. Note that irradiance measured 
below the center of the light source is much greater than that measured at the periphery. 
Measurements should be made with a radiometer specified by the manufacturer of the 
phototherapy system, If total serum bilirubin levels approach or exceed the exchange 
transfusion line, the sides of the bassinet, incubator, or warmer should be lined with 
aluminum foil or white material. This will increase the surface area of the infant exposed and 
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increase the efficacy of phototherapy.51 If the total serum bilirubin does not decrease or 
continues to rise in an infant who is receiving intensive phototherapy, this strongly suggests 
the presence of hemolysis. Infants who receive phototherapy and have an elevated direct-
reacting or conjugated bilirubin level (cholestatic jaundice) may develop the bronze-baby 
syndrome.  
2. Exchange transfusion Double volume exchange transfusion (DVET) should be 
performed if the TSB levels reach to age specific cut-off for exchange transfusion or the 
infant shows signs of bilirubin encephalopathy irrespective of TSB levels. Indications for 
DVET at birth in infants with Rh isoimmunization include[45]: 
 1. Cord bilirubin is 5 mg/dL or more  
2. Cord Hb is 10 g/dL or less 
 At birth, if a baby shows signs of hydrops or cardiac decompensation in presence of 
low PCV (<35%), partial exchange transfusion with 50 mL/kg of packed cells should be done 
to quickly restore oxygen carrying capacity of blood. The ET should be performed by pull 
and push technique using umbilical venous route. Umbilical catheter should be inserted just 
enough to get free flow of blood [46]. 
 
GUIDELINES FOR EXCHANGE TRANSFUSION FOR INFANTS ≥35 WEEKS 
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Guidelines for exchange transfusion in infants 35 or more weeks’ gestation. Note that 
these suggested levels represent a consensus of most of the committee but are based on 
limited evidence, and the levels shown are approximations. for risks and complications of 
exchange transfusion. During birth hospitalization, exchange transfusion is recommended if 
the TSB rises to these levels despite intensive phototherapy. For readmitted infants, if the 
TSB level is above the exchange level, repeat TSB measurement every 2 to 3 hours and 
consider exchange if the TSB remains above the levels indicated after intensive phototherapy 
for 6 hours.The following B/A ratios can be used together with but in not in lieu of the TSB 
level as an additional factor in determining the need for exchange transfusion52: If the TSB is 
at or approaching the exchange level, send blood for immediate type and crossmatch. Blood 
for exchange transfusion is modified whole blood (red cells and plasma) crosshatched against 
the mother and compatible with the infant 
3. Intravenous immunoglobulin’s (IVIG)  
IVIG reduces hemolysis and production of jaundice in isoimmune hemolytic anemia 
(Rh isoimmunisation and ABO incompatibility) and thereby reduces the need for 
phototherapy and exchange transfusion. We give IVIG (0.5 to 1 gm/kg) in all cases of Rh 
isoimmunisation and selected case of ABO incompatibility with severe hemolysis. IVIG 
administration can cause intestinal injury and necrotizing enter colitis.  
4. IV hydration  
Infants with severe hyperbilirubinemia and evidence of dehydration (e.g. excessive 
weight loss) should be given IV hydration. An extra fluid of 50 mL/kg of N/3 saline over 8 hr 
decreases the need for exchange transfusion[47]. 
 5. Other agents 
 There is no proven evidence of benefit of drugs like phenobarbitone, clofibrate, or 
steroids to prevent or treat hyerbilirubinemia in neonates and therefore these agents should 
not be employed in treatment of jaundiced infants. 
 
PROLONGED JAUNDICE 
 There is no good definition of prolonged jaundice (PJ). Generally, persistence of 
significant jaundice for more than 2 wk in term and more than 3 weeks in preterm babies is 
taken as PJ. Though, it is not uncommon to see persistence of mild jaundice in many infants 
for 4 to 6 weeks of age. Most of these babies do well without any specific intervention or 
investigation. The first and foremost step to manage an infant with PJ is to rule out 
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cholestasis (Figure 2). Yellow colored urine is a reasonable marker for cholestasis; however 
the urine color could be normal during initial phase of cholestasis. For the practical purpose, 
an infant with PJ with normal colored urine can be considered to have unconjugated 
hyperbilirubinemia. If the infant has dark colored urine, the infant should be managed as per 
cholestasis guidelines[48]. Infants with true PJ (unconjugated hyperbilirubinemia) should be 
assessed clinically for severity and possible cause of prolongation of jaundice. If the clinical 
assessment of jaundice suggests TSB levels below phototherapy cut offs for age (say <15 to 
18 mg/dl interm infant ), the infant may not be subjected to any unnecessary investigations. 
As many of these infants have PJ as a result of inadequate feeding, appropriate measures are 
taken to optimize breastfeeding. Thyroid screen can be considered in such infants at this stage 
if routine metabolic screen for hypothyroidism has not been carried out at birth. 
 If baby appears significant jaundice at this stage, TSB level should be performed and 
possible underlying cause should be looked for. In such infants, G6PD level, thyroid screen, 
ABO of infant & mother if not done earlier should performed to delineate possible cause. 
Infants having TSB in phototherapy range should be started on phototherapy[49]. The 
adequacy of breastfeeding should be assessed by history, observation of breastfeeding 
session, and degree of weight loss. Many of the mothers, even at this stage, have persisting 
breastfeeding problems such as poor attachment, sore nipple etc. 
 Breast mild jaundice (BMJ) is relatively a common cause of jaundice, but, 
inadequacy of breastfeeding being more common than it should be carefully ruled out. BMJ 
being an innocuous entity, cessation of breastfeeding is not required in practically any case. 
Infants with BMJ should be treated with phototherapy, if required. For a rare infant with TSB 
hovering in exchange range, a brief trial of interruption of breastfeeding can be considered. 
We haven’t stopped breastfeeding even for once for treatment of BMJ in last 15 years! 
 In an infant failing to respond to these measures, a diagnosis of CNS should be 
entertained. A trial of phenobarbitone can be considered to establish the diagnosis[50]. 
 
PATIENT EDUCATION 
Parents should be educated about neonatal jaundice and receive written information 
prior to discharge from the birth hospital. The parent information leaflet should preferably be 
available in several languages. 
A novel 2-color icterometer (Bilistrip) appears to have the potential to facilitate early 
maternal detection of clinically significant jaundice and help them in decision making to seek 
INTRODUCTION 
 
THE ERODE COLLEGE OF PHARMACY  30 
 
medical treatment. In a study that trained mothers in a maternity hospital to use the 
icterometer on the blanched skin of their infant's nose to determine absence (light yellow) or 
presence (dark yellow) of significant jaundice, there was a 95.8% sensitivity and 95.8% 
negative predictive value for detecting infants requiring phototherapy. 
A smart phone application (BiliCam) has also been developed to assess neonatal 
jaundice. It shows promise for effectively screening newborns in a diverse sample of 
newborns (age <7 days), including black, Hispanic, and Asian infants. In a study comprising 
530 newborns whose estimated bilirubin levels were calculated and compared with total 
serum bilirubin levels, the use of 2 decision rules resulted in the application providing 
accurate estimates of total serum bilirubin levels.  
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RIVIEW OF LITERATURE 
 
Ronald S. Cohen et al., conducted a study about the neonatal jaundice in infants.it 
can be best understood as a balance between the production and elimination of bilirubin, with 
a multitude of factors and conditions affecting each of these processes. When an imbalance 
results because of an increase in circulating bilirubin (or the bilirubin load) to significantly 
high levels (severe hyperbilirubinemia), it may cause permanent neurologic sequelae 
(kernicterus). In most infants, an increase in bilirubin production (e.g., due to hemolysis) is 
the primary cause of severe hyperbilirubinemia, and thus reducing bilirubin production is a 
rational approach for its management. The situation can become critical in infants with an 
associated impaired bilirubin elimination mechanism as a result of a genetic deficiency and/or 
polymorphism. Combining information about bilirubin production and genetic information 
about bilirubin elimination with the tracking of bilirubin levels means that a relative 
assessment of jaundice risk might be feasible. Information on the level of bilirubin production 
and its rate of elimination may help to guide the clinical management of neonatal jaundice[51]. 
Blackburn S et al.,conducted a study to find out Jaundice is a common physiologic 
problem seen  in both term and preterm infants. Normal transitional changes in bilirubin 
metabolism lead to physiological jaundice in many infants. In some infants these normal 
changes at birth may be exaggerated, such as occurs with immaturity, or may interact with 
health alterations (pathologic jaundice), result ing in the accumulation of excess bilirubin and 
development of hyperbilirubinemia. Caregivers must appreciate the processes and the basis 
for physiologic jaundice and hyperbilirubinemia and recognize infants at risk for these 
disorders. This article reviews neonatal bilirubin metabolism as a basis for understanding the 
causes and treatment of physiologic jaundice and hyperbilirubinemia arising from either 
physiologic or pathologic causes. Patterns of bilirubin in breast fed infants are discussed 
along with other issues related to breast feeding and jaundice. Treatment of 
hyperbilirubinemia and implications for nursing assessment and management of infants under 
phototherapy are also described[52]. 
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McKiernan P et al., conducted a study to find out the Neonatal jaundice lasting 
greater than 2 weeks should be investigated. Pale stools and dark or yellow urine are evidence 
of liver disease, which should be urgently investigated. The neonatal hepatitis syndrome has 
many causes, and a structured approach to investigation is mandatory. It should be possible to 
confirm or exclude biliary atresia within one week, so that definitive surgery is not delayed 
unnecessarily. Babies with the neonatal hepatitis syndrome should have vigorous fat-soluble 
vitamin supplementation, including parenteral vitamin K if coagulation is abnormal. The 
prognosis for infants with idiopathic neonatal hepatitis and multifactorial cholestasis is 
excellent[53]. 
 
Ronald J. Wong et al., conducted a study about the Cleavage of the alpha-methene 
bridge of heme by membrane-bound heme oxygenase yields equimolar amounts of biliverdin, 
carbon monoxide, and reduced iron. Biliverdin is catalyzed by biliverdin reductase to 
bilirubin. The process occurs in all nucleated cells except mature anucleated red blood cells. 
Neonates in whom bilirubin production is increased tend to have higher bilirubin 
concentrations, and excessive bilirubin production or impairment of elimination causes 
dramatic deviations from the hour-specific nomogram that can be seen as “jumping” 
percentile tracks early in the postnatal period or later in the first week after birth. After 
formation, bilirubin diffuses into the circulation. In the absence of conjugates, the total 
bilirubin concentration in plasma is the sum of bilirubin bound to albumin plus a minimal 
amount of free bilirubin. Bilirubin is excreted more slowly in newborns than in adults. 
Although no clinical tests can measure bilirubin uptake and conjugation by the liver, an 
elevated hour-specific total bilirubin value when bilirubin production is normal or decreasing 
is a sign of impaired or abnormally delayed bilirubin excretion. The accuracy and precision 
of clinical laboratory total bilirubin measurements are a concern, and studies are underway to 
assess whether measurements of free bilirubin, the bilirubin-binding constant, the 
bilirubin:albumin ratio, or albumin binding capacity might improve the ability to identify 
infants at greater risk for bilirubin-induced neuroinjury rather than simply those at greater 
risk for having a higher bilirubin concentration[54]. 
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V K Bhutani, R J Vilms et al.,conducted a study to find out the severity of jaundice. 
To reduce the incidence of severe neonatal hyperbilirubinemia affecting newborns with 
jaundice in the United States and to prevent kernicterus, there is a need to implement 
proven prevention strategies for severe neonatal hyperbilirubinemia as recommended in 
the 2004 American Academy of Pediatrics Guidelines for newborns >35 weeks gestational 
age. The purpose of universal predischarge bilirubin screening is to identify infants with 
bilirubin levels >75th percentile for age in hours and track those with rapid rates of 
bilirubin rise (>0.2 mg per 100 ml per h). Early identification has been reported to predict 
severe hyperbilirubinemia and allow for evidence-based targeted interventions. A systems 
approach is likely to reduce the preventable causes of acute bilirubin encephalopathy. To 
do so, highest priority should be given to (i) designating extreme hyperbilirubinemia (total 
serum bilirubin >427 μmol l−1 or >25 mg per 100 ml) as a reportable condition by 
laboratories and health-care providers through public health mandates; (ii) implementation 
of Joint Commission's Sentinel Report for kernicterus; (iii) nursing outreach to 
communities for education of prospective parents; (iv) development of clinical pathways 
to monitor, evaluate and track infants with extreme hyperbilirubinemia; and (v) societal 
awareness. These efforts should be monitored by a state and national surveillance system 
in order to critically improve the timeliness and completeness of notifications and to allow 
evaluation and interventions at the policy and individual family level [55]. 
Jon F Watchko et al.,conducted a study  and  Advances in the clinical assessment 
strategies used to identify neonates at risk for the development of severe hyperbilirubinemia 
and bilirubin neurotoxicity, as well as the treatment measures to control hyperbilirubinemia 
in newborns, continue to be made. They include, among others, universal predischarge birth 
hospitalization bilirubin screening, the confirmation that hemolysis is an important risk factor 
for bilirubin neurotoxicity, the use of a numeric scoring system to help stage the severity of 
acute bilirubin encephalopathy, the potential advantages of turquoise-light phototherapy, and 
the potential role of heme-oxygenase inhibitors in preventing the need for exchange 
transfusions, all of which are reviewed here[56]. 
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Jean M Kirk et al., conducted a study about the biliurubin concentration in 
neonates.Neonatal jaundice is common, and usually harmless, because of physiological 
jaundice or breast-feeding. In some neonates unconjugated bilirubin concentration, coupled 
with other risk factors, is sufficient to allow free bilirubin to cross the blood-brain barrier and 
cause kernicterus. Another subgroup of infants is jaundiced because of elevated conjugated 
bilirubin; a marker for a number of pathological conditions. Bilirubin measurement must 
identify those infants at risk. Transcutaneous bilirubin measurement is increasingly used in 
healthy infants, especially before early discharge or at home, to assess the need for laboratory 
bilirubin measurement. Transcutaneous measurements are not covered by laboratory quality 
assessment schemes. Guidelines on management of neonatal jaundice utilize age in hours and 
other risk factors to define bilirubin action thresholds, which may be as low as 100 μmol/L 
for sick premature infants, whereas early discharged babies may only present after bilirubin 
concentrations are extremely high. Hence, there is a requirement for accurate total bilirubin 
measurement from <100 to >500 μmol/L, with sufficient precision to assess the rate of 
bilirubin change with time. Babies presenting with late jaundice always require conjugated 
bilirubin measurement. It is of concern that many total and direct bilirubin automated kit 
methods suffer from haemolysis interference, while use of in-house methods or modification 
of commercial methods has virtually disappeared. External quality assessment has a vital role 
in providing data on different methods' performance, including accuracy, precision and 
susceptibility to interference. Laboratories should consider whether their adult bilirubin 
methods are suitable for neonates[57]. 
 Janki Deshmukh et al., Conducted a study about the  Neonatal jaundice requiring 
phototherapy is associated with significant socioeconomic burden including hospital 
readmission, prolonged hospital stay, and separation of the baby from mother. To assess the 
efficacy and safety of probiotics in reducing the need for phototherapy and its duration in 
neonatal hyperbilirubinemia.the methods are used A systematic review of randomized 
controlled trials (RCTs) of probiotic supplementation for prevention or treatment of jaundice 
in neonates (any gestation or weight) using the Cochrane methodology. Primary outcome was 
the duration of phototherapy. Secondary outcomes included incidence of jaundice, total 
serum bilirubin (TSB) level at 24, 48, 72, 96 h, and day 7, duration of hospital stay, and 
adverse effects (e.g. probiotic sepsis). Results were summarized as per GRADE guidelines. It 
resultes Nine RCTs (prophylactic: six trials, N = 1761; therapeutic: three trials, N = 279) with 
low to high risk of bias were included. Meta-analysis (random-effects model) showed 
RIVIEW OF LITERATURE 
 
THE ERODE COLLEGE OF PHARMACY  35 
 
probiotic supplementation reduced duration of phototherapy [N = 415, mean difference (MD): 
−11.80 (−17.47, −6.13); p < .0001; level of evidence (LOE): low]. TSB was significantly 
reduced at 96 h [MD: −1.74 (−2.92, −0.57); p = .004] and 7 d [MD: −1.71 (−2.25, 
−1.17); p < .00001; LOE: low] after probiotic treatment. Prophylactic probiotics did not 
reduce the incidence of jaundice significantly [N = 1582, relative risk (RR): 0.56 (0.25, 
1.27); p = .16; LOE: low]. There were no probiotic-related adverse effects. and the 
experiment was found the Limited low-quality evidence indicates that probiotic 
supplementation may reduce the duration of phototherapy in neonates with jaundice. Routine 
use of probiotics to prevent or treat neonatal jaundice cannot be recommended. Large well-
designed trials are essential to confirm these findings[58]. 
 Olayinka O Goodman et al., (2016) conducted a  community-based survey was 
conducted amongst mothers aged 15–49 years living in Mosan-Okunola, Lagos, Nigeria to 
determine the knowledge of, attitudes to, preventive and treatment practices towards neonatal 
jaundice (NNJ).The mothers were selected using a multi-stage sampling technique. A pre-
tested interviewer-administered structured questionnaire was used to obtain data. The 
knowledge of the mothers was scored and scores lower than 50% were graded as poor, 50–
74% as fair and ≥75% as good. The practice was also categorised as appropriate if one correct 
option was identified and was categorised as inappropriate where an incorrect option(s) was 
identified singly or in combination with a correct option.the results is Three hundred and 
fifty-eight mothers were recruited. The mean age was 34.8 ± 9.05 years. Two hundred and 
seventy (75.4%) mothers had ever heard about the condition. Two hundred and forty-seven 
(91.4%) mothers correctly identified the condition and infection was the only most common 
known cause (47%). Only 34% of the mothers knew that NNJ could cause brain damage, and 
40% identified refusal of feeds as a danger sign. Up to 64% of the mothers believed attending 
antenatal care could prevent the condition, and 58% were of the opinion that exposing babies 
to sunlight could prevent the condition. Sixty-eight percent (68.9%) of the mothers had a poor 
level of knowledge. Age and educational qualification did not show any statistically 
significant relationship with knowledge about NNJ (P < 0.05) but increasing maternal age 
had a significant association with an appropriate treatment practice (P < 0.05), the association 
was negative (r = −0.32). this experiment is helps to Knowledge about NNJ was low in this 
community and ineffective preventive practices were utilised. Efforts should be made to 
increase it, and health workers should play a leading role[59]. 
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Roya Raeisi et al., (2017) conduted a systemtic review of  neonatal jaundice. 
Neonatal jaundice is one of the most common diseases among neonates that may cause 
irreparable complications such as kernicterus. This systematic review article was conducted 
to report and introduce medicinal plants that are used to treat neonatal jaundice in Iranian 
traditional medicine. To conduct this systematic review, the terms jaundice and icterus 
combined with the terms ethnobotanical, ethno-medicinal plants, ethnopharmacology, 
phytotherapy, and Iran were used to search for potentially relevant publications in Google 
Scholar, and Scientific databases ISI, PubMed, and Scopus. According to ethnobotanical 
evidence, six plant species from five families consisting of Cotoneaster discolour, Ziziphus 
jujube Miller, Hordeum vulgare L., Alhagi graecorum Boiss, Fumaria parviflora, 
and Chicorium intybus have been more frequently reported to be used to treat neonatal 
jaundice in Iran on which a number of studies have been conducted. However, a combination 
of two or more number of these plants has been reported to be used for treating neonatal 
jaundice. Although the plants and their compounds cause reduction in neonatal jaundice 
through different mechanisms of action, they cannot be considered an independent treatment 
in most cases. Therefore, it is recommended to use plants and their compounds as a 
complementary treatment to reduce bilirubin[60]. 
 
Nasrin Khalesi et al., (2008) to conduct a cross sectionel study A cross-sectional 
study, was done on 400 mothers, who delivered at Ali-Ebne Abitaleb hospital in Zahedan-
Iran during April and May 2006.To determine knowledge, attitude, and behaviour of mothers 
about neonatal jaundice In this cross-sectional study, 400 cases who delivered at Ali-Ebne 
Abitaleb Hospital in Zahedan-Iran during April and May 2006 were interviewed to complete 
21-point questionnaires. The first data was analyzed descriptively then analytically by c2, 
Pearson correlation, and independent t-test using SPSS 11 software.The mean age of mothers 
was 26.8±6.5 years. The mean of knowledge score was 7.25±2.1 out of 13.5. Although 
knowledge of mothers about diagnostic methods was acceptable, it was not sufficient about 
causes, complications, harmful symptoms and prevention of the disease. The mean of attitude 
score was 18.5±3.7 out of 25. The mean of behaviour score was 6.8±2.3 out of 10.5. 
Knowledge had a significant association with history of neonatal jaundice (P=0.033), 
mother's age (P<0.001), and child's birth rank (P=0.001). There was also a significant 
association between mother's attitude and their educational level (P<0.001). Results showed a 
direct correlation between knowledge, attitude and behaviour (P<0.001). Increasing mothers' 
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knowledge about jaundice of neonates can be the first step to enhance healthy behaviours; 
through education programmes during pregnancy (JPMA 58:671; 2008)[61].  
 
Sahoo M et al., (2016) to conduct a prospective study at ASRAM Medical College 
and Hospital, a tertiary care centre, Eluru, West Godavari District, Andhra Pradesh Some of 
the most common causes of neonatal jaundice include physiological jaundice, breast feeding 
or non feeding jaundice, breast milk jaundice, prematurity and ABO incompatibility. Aims 
and objectives of study IS To study the incidence, various risk factors in newborns with 
clinical jaundice progressing to jaundice needing treatment and to assess no of neonates 
requiring phototherapy & exchange transfusion in ASRAM hospital, during May 2013 to July 
2014. Method: The present study was a prospective hospital based study involving all 
neonates who were born at ASRAM Medical College and Hospital, a tertiary care centre, 
Eluru, West Godavari District, Andhra Pradesh. Observation: Out of 560 newborns, 273 
(48.8%) newborns developed clinical jaundice. Out of 273 newborns with clinical jaundice, 
166 (61%) newborns developed physiological jaundice and 107 (39%) newborns developed 
non physiological jaundice requiring therepeutic intervention in the form of phototherapy or 
exchange transfusion. Conclusion: Present study concludes that the leading cause of 
pathological jaundice is breastfeeding jaundice, ABO incompatibility and prematurity[62]. 
Daynia E. Ballot and Gilbert Rugamba et al., conducted a study . Exchange 
Transfusion for Neonatal Hyperbilirubinemia in Johannesburg, South Africa, from 2006 to 
2011 Severe hyperbilirubinaemia requiring exchange transfusion has become less common in 
recent years; however, kernicterus still occurs. The aim of this study was to review babies 
undergoing exchange transfusion for severe hyperbilirubinaemia in a Johannesburg hospital. 
This was a retrospective review of babies who required exchange transfusion in both the 
neonatal and the paediatric wards from June 1, 2006, to December 31, 2011. Results. There 
were 64 patients who underwent 67 exchange transfusions. Isoimmune haemolysis (both Rh 
and ABO incompatibility) was the cause of jaundice in 9/64 (14%). Most babies who 
underwent exchange transfusion were sick or preterm and were admitted in hospital after 
birth (38/64; 59.5%); three of these babies died, but not during the exchange transfusion 
(3/38; 7.9%); all three had signs suggestive of neonatal sepsis. The remaining 26 babies 
(40.6%) were readmitted to the paediatric wards for exchange transfusion. Six of these babies 
(6/26; 23.0%) had signs of kernicterus. The most significant complication of exchange 
transfusion was apnoea requiring mechanical ventilation in three patients (3/64; 4.6%). The 
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conclusion of this study is. Despite a relatively low number of babies undergoing exchange 
transfusion, kernicterus still occurs and must be prevented. Proper protocols for screening and 
management of severe hyperbilirubinaemia need to be enforced[63]. 
Heier HE, et al.,The present prospective study indicates that children of mothers with 
blood group O run a double risk of hyperbilirubinemia requiring treatment as compared to 
children of mothers of blood group A, and 5-10 times increased risk of needing exchange 
transfusion. The most frequent cause of need for exchange transfusion was ABO-
incompatibility between mother and child. A positive direct ant globulin reaction in an ABO-
incompatible child in need of treatment doubles the risk of exchange transfusion being 
required. Blood group O in the mother should be considered to be an independent risk factor 
for the child, and O-pregnant women should be ABO-grouped for this reason[64]. 
 Lucas GN.,A prospective study was carried out on 101 neonates with jaundice due to 
ABO incompatibility. The direct Coomb's test was weakly positive in 4 cases. The indirect 
Coomb's test using the eluate was positive in 8 cases. In the maternal blood either IgG anti-A 
or anti-B haemolysin was present in high titer in every case. Phototherapy was given when 
the indirect serum bilirubin level exceeded 9 mg/dl. Exchange transfusion was done-in 39 
cases, 9 babies requiring multiple exchanges. There were 2 deaths[65]. 
Beazley JM, et al., studied of 1353 labours and the relevant newborn failed to reveal 
any significant difference between the incidence of neonatal hyperbilirubinemia (defined as a 
level of 12 mg. or more per 100 ml.) following spontaneous labour, and after labour induced 
or accelerated by oxytocin. The incidence of unexplained neonatal hyperbilirubinemia after 
spontaneous labour was 6-3 per cent. Following induced labour however there was a highly 
significant (P less than 0-001) association between the mean total dose of oxytocin used for 
induction and the incidence of neonatal hyperbilirubinemia. The proportion of babies who 
developed hyperbilirubinemia increased in direct relation to the total dose of oxytocin used 
for the induction. In this series the incidence of hyperbilirubinemia increased sharply when 
the total dose of oxytocin exceeded 20 units as it did hyperbilirubinemia and birth weight, or 
duration of spontaneous labour. When labour was induced, however, the proportion on 
newborn babies with hyperbilirubinemia increased with the duration of labour. The 
significance of these findings is discussed[66]. 
Corchia–et al studied idiopathic hyperbilirubinemia (in Sardinian infants) in the first 
4 days of life among 431 healthy full term infants with birth weight >2,500 gms.  All infants 
RIVIEW OF LITERATURE 
 
THE ERODE COLLEGE OF PHARMACY  39 
 
were free from malformations or any disease, requiring treatment other than jaundice.  They 
were ABO and Rh incompatible with their mothers and were not G6PD deficient.  The 
regression analysis indicated that high alpha-fetoprotein concentrations in cord blood. History 
of neonatal jaundice in previous full term siblings, delayed first meconium passage and 
weight loss were associated with jaundice.  These results suggest the high rate of 
constitutional and possible hereditary factors[67]. 
Rosenthal–et al.– assessed liver function and hyperbilirubinemia in the newborn.  
“Liver Function” is assessed, by either measuring the concentration of substances produced 
by the hepatocyte, measuring the serum content of substances that are changed by hepatocyte 
damage.  Evaluating the serum concentrations of substances released from the cells as a result 
of injury, assessing the ability of the liver to perform a metabolic task such as conjugation or 
detoxification, or by measuring enzyme activity and substitute content of the cell and its 
organisms.  After birth with cessation of placental functions, the neonatal liver must assume 
many different tasks.  Distinct developmental sequences rapidly progress for numerous 
hepatic functions as the newborn adapts to its environment.  Lastly they concluded that the 
manuscript is an attempt to provide guidelines for the evaluation and management of the 
newborn infant by assessing live function and hyperbilirubinemia[68]. 
 
 
Gartner LM et al., studied Optimal management of breastfeeding does not eliminate 
neonatal jaundice and elevated serum bilirubin concentrations. Rather, it leads to a pattern of 
hyperbilirubinemia that is normal and, possibly, beneficial to infants. Excessive frequency of 
exaggerated jaundice in a hospital or community population of breastfed infants may be a 
warning that breastfeeding policies and support are not ideal for the establishment of good 
breastfeeding practices. The challenge to clinicians is to differentiate normal patterns of 
jaundice and hyperbilirubinemia from those that indicate an abnormality or place an infant at 
risk[69]. 
 B Wood, P Culley, et al., conducted a study Plasma bilirubin was estimated on 690 
term infants on about the 6th day of life. Perinatal factors were recorded and the results 
analysed. Hyperbilirubinemia was defined as a level greater than 205 micromol/1 (12 mg/100 
ml) and this was present in 20% of cases. Three factors-- epidural analgesia, breast feeding, 
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and poor weight recovery--showed highly significant associations with jaundice. The relative 
importance of these is discussed and compared with recent reports. Induction of labour, for 
reasons other than postmaturity, and a gestational age less than 39 weeks showed a slightly 
increased incidence of jaundice. There was no correlation with other factors tested including 
oxytocin drug administration. Despite the high incidence (20%) of hyperbilirubinemia, only 
2.5% infants needed treatment and none required exchange transfusion. Radical changes in 
obstetric management or infant feeding are not indicated[70]. 
Ablfors – et al. performed a study on the criteria for exchange transfusion in 
jaundiced newborns, which lowers critical bilirubin concentrations when the serum albumin 
falls to <2.5 g/dl.  This study investigates using the biirubin / albumin ration instead of the 
single albumin concentration eliminate this potential ambiguity in the criteria.  They 
concluded that the bilirubin / albumin ration is a simple, non-ambiguous way of incorporating 
the serum albumin concentration in to exchange transfusion criteria.   The bilirubin / albumin 
ratio was defined as a reliable indicator of bilirubin / albumin binding of the frequency curves 
of specific unbound bilirubin concentrations are normally distributed functions of the ratio.  
Therefore, the bilirubin / albumin ratios at which the unbound bilirubin reached the 10, 15 
and 20 nmon/1 were determined by the peroxides method in 35 well full term, 10 ill full term 
and 19 ill pre term neonates.  The frequency curves for each unbound bilirubin concentration 
was plotted against the bilirubin / albumin ratio were tested for normality.  Furthermore, the 
mean ratio at which each unbound bilirubin occurred did not differ significantly among the 
groups of neonates.  The author concluded that the bilirubin / albumin ratio is a simple, non-
ambiguous way of incorporating the serum albumin concentration into exchange transmission 
criteria[71]. 
Rubaltelli – et al.  Carried out a study on management of neonatal 
hyperbilirubinemia and prevention of kernicterus. Hyperbilirubinemia remains as one of the 
most common and more important pathological conditions in the newborn. Current 
methodologies for suppressing severe neonatal jaundice include; (a) attempts to stimulate 
liver conjugating enzymes using drugs such as Phenobarbital; (b) attempts to degrade 
bilirubin with phototherapy; and (c) exchange transfusion. It is too soon to consider tin-
protoporphyrin as a drug for the prevention and treatment of neonatal hyperbilirubinemia. 
However, if it can be shown that tin-protoporphyrin can serve as a safe and less costly 
alternate treatment, a considerable improvement in the management of neonatal jaundice can 
be achieved[72]. 
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Tan - et al. studied the efficacy of “high-intensity” blue-light and “standard” daylight 
phototherapy for non hemolytic hyperbillirubinemia. They stated that, nursing of infants 
under high-intensity blue light was more difficult and inconvenient as was clinical 
monitoring. The light also cause more stress to the nursing and medical personnel. However, 
the infants tolerated both types of phototherapy equally well. High-intensity blue-light 
phototherapy would seem to be the treatment of choice for infants with rapidly increasing or 
very high bilirubin levels, as well as, in those not responding adequately to daylight 
phototherapy. And carried  out a study on phototherapy and the brain-stem auditory evoked 
response in neonatal hyperbilirubinemia, The brain-stem auditory evoked response of infants 
with hyperbilirubinemia were significantly greater before phototherapy than after 
phototherapy. Theses values of the brain stem auditory-evoked response improved 
significantly during phototherapy and correlated significantly with the declining bilirubin 
levels. Improvement continued after phototherapy, despite a rebound of serum bilirubin 
concentrations[73].  
Altha Roberts Edgren - Full-term infants rarely require an exchange transfusion if 
intense phototherapy is initiated in a timely manner. It should be considered if the total serum 
bilirubin level is approaching 20 mg/dL and continues to rise despite intense in-hospital 
phototherapy. Exchange transfusion corrects anemia associated with the destruction of red 
blood cells and is effective in removing sensitized red blood cells before they are destroyed. 
It also removes about 60 percent of bilirubin from the plasma, resulting in a clearance of 
about 30 percent to 40 percent of the total bilirubin. If a transfusion is not performed and 
bilirubin levels get higher, the infant progresses through three phases. In the first two to three 
days the infant is lethargic, has muscle weakness, and sucks weakly. Progression is marked 
by a tensing of the muscles, arching, fever, seizures, and high-pitched crying. In the final 
phase, the patient is hypotonic for several years[74]. 
Newman – et al. examined the association between neonatal bilirubin levels and 
subsequent neuro developmental outcome.  He carried out a study on 41, 24 singleton white 
or black infants with birth weight > 2.500 gms, who had neonatal bilirubin measurement 
recorded and survived at least 1 year.  Lastly, he concluded neonatal bilirubin levels seem to 
have little effect on IQ, definite neurological abnormalities or hearing loss.  Higher bilirubin 
levels are associated with minor motor abnormalities[75].  
Bysshe studied deafness in childhood.  In his study, he stated the risk factors for 
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deafness are low birth weight, neonatal jaundice, family history of deafness etc.  
De-Caceres – et Al. evaluated behavioral differences in healthy newborns in 
relationship to bilirubin serum levels within the normal physiological range.  They concluded 
that physiological bilirubin levels cause significant neurological disturbances; these results 
suggest that newborns with higher physiological bilirubin levels have some difficulties 
interacting with their caretakers[76].  
Ozmert – et al. carried out a retrospective follow up study to evaluate the suitability 
of the recently reported exchange transfusion limits (serum indirect bilirubin level of 428-496 
mumol/1, 25-29 mg/dl) for Turkey.  Children were grouped according to their maximum 
serum bilirubin levels and direct Coomb’s test results.  Physical and neurological 
examinations, visual and brainstem auditory evoked potentials and the Wechsler Intelligence 
Scale for children were performed.  They concluded that children whose direct Coomb’s tests 
were positive, had significantly lower IQ scores and more prominent neurological 
abnormalities (P<0.05)[77]. 
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NEED FOR THE STUDY 
 
       The role of developmental assessment is to see that the child is progressing as per norms set 
by a large majority of children of the same age.  It is by no means a predictor of future intelligent 
quotient and any deviation from the normal is brought to the notice of the parents, only in 
reassuring ways. The cause and effect relation between developmental deficits and risk factors 
can be much more complicated than we imagine. We cannot presume that neonatal jaundice will 
lead to mental retardation, fine and gross motor abnormalities, hearing loss and vision problems.  
But most of the children have developmental disabilities after neonatal jaundice. 
 
        Hence it is ideal to have some sort of developmental evaluation for all babies like 
measuring length, Head Circumference, Chest Circumference, Midarm Circumference, weighing 
weight & reflexes of the neonates. The Preliminary analysis and statistics from many child 
developmental centers and out-patient departments in hospitals have showed that babies with 
neonatal hyperbilirubinemia have higher incidence of delayed developmental milestones and 
other associated problems. 
 
Hence the investigators were prompted to follow the children who suffered from neonatal 
jaundice in order to identify the complications very early and promote optimum growth & 
development of the children. 
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AIM AND OBJECTIVE 
AIM 
The aim of this study is provides recommendations aimed to improve management of 
neonatal hyperbilirubinemia in infants. 
0BJECTIVE 
 To study the treatment used in the management of neonatal jaundice. 
 To study the sign , symptoms and duration of the diseases. 
 Collect information on the diagnosis, and treatments. 
 To assess the diagnosing methods. 
 Observe the entire treatment methods. 
 to establish the most effective treatment methods for neonatal jaundice 
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PLAN OF WORK 
 
 
 
• Initial study to identify the scope of work 
• Literature survey 
• Preparation of study of protocol 
• Obtaining consent  from the hospital authority 
• Collection of data format from  case sheets 
• Data analysis 
• Evaluations of data 
• Results and Discussion 
• Summary & Conclusion 
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METHODOLOGY 
Study site: The study is conducted in Government district headquarters hospital, Thirupur 
district, Tamil Nadu. 
Study period: November 2017 - June 2018 
Study type: Retrospective study 
Sample size: 80 patients 
Study population: babies attended in neonatal intensive care unit, case sheets from medical 
record department. 
Inclusion criteria: 
•  New birth babies diagnosed with neonatal jaundice 
• Patients those willing to give their consent. 
 Exclusion criteria 
• Patient above 6 month years old. 
• addult. 
Study procedure 
 
The present study was conducted at Government district headquarters hospital, Thirupur for the 
retrospective assessment of neonatal jaundice cases The study involves mainly 3 steps. 
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1-Collection of the prescriptions 
 
The prescription were collected from the neonetal intensive care unit, medical record department 
of Government district headquarters hospital, Thirupur. For a period of 6 months that is from Sep 
17 to feb 2018.The study was conducted in retrospective manner, The data was collected from 
the respective departments of the hospital on proforma. 
 
2-Analysing the prescription 
 
The Collected data from the prescription were entered in to proforma were analysed.  The 
phototherpy , its duration and other important parameters are noted. 
 
3-Statistical analysis 
The datas were collected according to the proforma and was entered in separate excel sheets in 
respective of their proformas or the parameters and they were analysed for the outcomes of the 
individual parameters like gender, age groups, others by making a table first and then followed 
by a graphical representation of the data. 
 
The study was designed in a Retrospective manner. It was conducted in babies neonatal  
Intensive care unit of Government district headquarters hospital, Thirupur district (Tamilnadu) 
from sep 2017-feb 2018. 
 
A study population of 80 patients (new babies and diagnosed with neonatal jundice) was 
selected. The study population consisted of both sex. 
 
Prescriptions were collected from the respective departments of the hospital. Collected Data 
were recorded using a predesigned proforma and entered in to Microsoft Excel worksheets. 
Appropriate tests were applied for analysis. 
Prevalence of neonatal joundice risk factors and , phototherapy frequency were noted. 
 
 
. 
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GENDER WISE DISTRIBUTION OF NEONALAL JAUNDICE 
 
Table -1 
 NO OF PATIENTS PERCENTAGE % 
MALE 44 55 % 
FEMALE 36 45 % 
TOTAL 80 100 % 
 
 
 
 
Figure-1 
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BODY WEIGHT DESTRIBUTION OF NEONATAL JAUNDICE CASES 
 
Table -2 
BODY WEIGHT FREQUENCY (n = 80) PERCENTAGE % 
NORMAL BODY WEIGHT 48 60 % 
LOW BODY WEIGHT 28 35 % 
VERY LOW BODY 
WEIGHT 
4 5 % 
 
 
Figure -2 
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DISTRIBUTION OF GESTATIONAL AGE OF NEONATAL JAUNDICE 
 
Table-3 
GESTATIONEL AGE FREQUENCY (n = 80) PERCENTAGE % 
TERM( > 35 WEEKS) 62 77.5 % 
NEAR TERM(35-37 WEEKS) 10 12.5 % 
PRE TERM(<35 WEEKS) 8 10 % 
 
 
 
Figure-3 
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TYPES OF MOTHER 
 
Table-4 
TYPE OF MOTHER FREQUENCY (n = 80) PERCENTAGE % 
NORMAL 57 71.2  % 
PRIMI MOTHER 23 28.8 % 
 
 
 
 
 
Figure-4 
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TYPE OF DELIVERY 
 
Table-5 
TYPE OF DELIVERY FREQUENCY(N=80) PERCENTAGE % 
NVD 31 38.7% 
LSCS 49 61.3% 
 
 
 
Figure-5 
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NO.OF RISK FACTERS IN PATIENTS 
 
Table-6 
RISK FACTER NO.OF NEONETES PERCENTAGE % 
LOW BIRTH WEIGHT 32 40% 
SEPSIS 28 35% 
FEVER 18 22.5% 
POOR FEEDING 38 47.5% 
PRIMI MOTHER 23 28.8% 
 
 
 
Figure-6 
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PHOTOTHERAPY DURATION 
 
Table-7 
DURATION (DAY) NO.OF PATIENTS PERCENTAGE 
2 DAYS 33 41.5% 
3 DAYS 21 26% 
4 DAYS 22 27.5% 
5+ DAYS 4 5% 
                                                                                                               
 
Figure-7 
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DISTRIBUTION OF BILURUBIN CONCENTRATION 
 
Table-8 
T.S.B 
CONCENTRATION 
(mg/dl) 
NO.OF PATIENTS 
(n=80) 
PERCENTAGE % 
5-10 22 27.5% 
10-15 52 65% 
15 above 6 7.5% 
 
 
 
 
Figure-8 
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DRUG PATTERN IN TREATMENT OF JAUNDICE ALONG WITH SEPSIS 
 
Table-9 
MEDICATION NO OF PATIENTS PERCENTAGE % 
Ampicillin 22 80 
Gentamycin 23 82.5 
Cefotaxime 18 65 
Piperacillin 3 10 
Amikacin 17 60 
 
 
Figure-9 
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DISCUSSION 
80 patients were selected for the retrospective study. The study population consisted 
of 44 male infants (55%) and 36 female infants (27%) Figure.1 
Neonates selected for the study had different body weight. It includes. Study 
population include normal body weight neonates (60%), low body weight neonates (35%) 
and very low birth weight neonates (5%). Infants with normal bodyweight found to be more 
susceptible to neonatal jaundice. And the low birth weight neonates are risk factor of neonatal 
jaundice.Figure.2 
The total infants are categorised on the basis of gestational weeks such as 
term(77.5%), near term (12.5%) and pre term (10%). The neonatal jaundice is mostly 
effected category is normal infants.Figure.3 
The primi para mother is the one of the risk factor of neonatal jaundice. The primi 
para mother have totaly 23 present the total case. that is the 30 % neonatal jaundice effected 
in the case of primi para mother.Figure.4 
61.3% of study population contain caesarean type delivery(LSCS).and 38.7% of 
mother in normal delivery (NVD).the caesarean infants are mostly effected neonatal jaundice 
than normal delivery infants .LSCS is also a risk factor of neonatal jaundice.Figure.5 
Among the study population ,the most prevalent risk factor was found to be poor 
feeding (47.5%) followed by low birth weight (40%) and effect of sepsis (35%). 28% of 
mothers are primi para type. 22.5% of infants effected in fever. Figure. 6 
Phototherapy treatment is the commonly used treatment of neonatal jaundice mainly 
the duration is mostly preferred to two days (41.5%) normally followed by four days (27.5%) 
and three days (26%).The duration depend up on the severity of jaundice. Only 5% is 
preferred to more than four days.Figure.7 
The bilurubin concentration is the main diagnostic tool of neonatal jaundice .The 
27.5%of the neonates contain bilurubin range is 5-10mg/dl most of the neonates (65%) 
contain the range of 10-15 mg/dl .Only 7% neonates is the higher bilurubin concentration 
level. That is mostly the bilurubin level is medium concentration.Figure.8 
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28 infants are effected jaundice along with sepsis and the drug pattern are used mainly 
antibiotics. Ampicillin and Gentamycin were the most commonly used antibiotic medication. 
Gentamycin was used in 23 patients (82.5) and Ampicillin was used in 22 patients 
(80%).Cefotaxime was used in 18 patients (65%) and Amikacin was used in 17 patients 
(60%) and Piperacillin was used in 3 patients (10%) out of 28 patients.Figure.9 
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CONCLUSION 
 Neonatal jaundice was found to be more prevalent in male infants compared to 
females. This reflects male gender is an important risk factor for neonatal jaundice. 
 The primipara mother is one of the most risk factor of neonatal jaundice. Near 50 % 
of infants found to be poor feeding. That is the main symptom of neonatal jaundice. 
 Sepsis effected to 35 % of the neonates. That is it’s also one of the most risk factor of 
neonatal jaundice. 
 Most of the infants about 65% of neonates effected to medium level of neonatal 
jaundice the range of bilirubin concentration is shown in to 10-15 mg/dl. 
 Birth weight of infants are affected .low birth weight of infants are also one of the risk 
factor. And gestational age of infants is effected rarely only 10% of pre term neonates 
are effected neonatal jaundice. 
 Bilirubin concentration is a highly sensitive parameter in detection of cases of 
neonatal jaundice. 
 Recommendation for the duration of photo therapy can be decided based on the 
results of visual assessment and total serum bilirubin concentration. 
 The phototherapy is the main treatment method of neonatal jaundice. It is an effective 
treatment method normally.drugs is not ordinarily used. 
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PROFORMA 
 
PATIENT DETAILS 
NAME : 
IP NO : 
SEX : 
AGE: days 
DOB: 
GESTATIONAL  AGE: 
BIRTH WEIGHT: 
CHIEF COMPLAINTS: 
DIAGNOSIS: 
OUTCOME OF HOSPITALIZATION: Survived [ ], Died [ ], Unknown [ ] 
MOTHER’S DETAILS 
NAME : 
AGE : 
BLOOD TYPE: 
TYPE OF DELIVERY: 
PAST MEDICATION HISTORY : 
PREVIOUS COMPLICATIONS OF PREGNANCY: 
PARA:    GRAVIDA: 
 
 
 
 
  
 
PRESENCE OF ANY OF THE FOLLOWING :      Y/N 
 Prematurity ˂ 38 weeks            [   ] 
 Low birth weight            [   ] 
 History of hyperbilirubinemia            [   ] 
 ABO/ Rh incompatibility             [   ] 
 Non optimal feeding             [   ] 
 Central hematocrit more than 65%          [   ] 
 Presence of signs of underlying illness like 
     Vomiting/lethargy/poor feeding/temperature instability/apnea.     [   ]  
 Jaundice visible on the first day of life         [   ] 
 Newborn's trunk is distinctly yellow stained 
  with yellow tinge of palms and soles.          [   ] 
 Geographic prevalence of G-6PD deficiency          [   ] 
 Primipara mother            [   ] 
 Reduced sucking            [   ] 
 Fever             [   ] 
 Other infections eg septicemia, UTI          [   ] 
 Diarrhoea             [   ]  
 
 
 
 
  
 
DAY 1 
General physical examination: 
Wt:        Icterus:  
Color:         Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :       TWC:   
Platelet count:      CRP:    
Blood culture:  
Serum Bilurubin : 
 Total :  
 Direct: 
Treatment: 
 
 
DAY 7 
General physical examination: 
Wt:        Icterus:                  
Color:                    Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :        TWC:    
Platelet count:       CRP:    
Blood culture: 
Serum Bilurubin : 
 Total :  
 Direct: 
 
Treatment : 
 
DAY 14 
General physical examination: 
Wt:        Icterus:                  
Color:                    Abdomen:  
Vital signs: 
Temp:                            HR:                                 
RR: 
Laboratory investigations:  
Hb :        TWC:    
Platelet count:       CRP:    
Blood culture: 
 Serum Bilurubin : 
 Total :  
 Direct: 
 
Treatment : 
 
 
OTHER  INFORMATION: 
 INFORMED CONSENT 
 
Participant written informed consent 
 I understand that my participation is voluntary and that I may withdraw from this study at 
any time without giving any reason or to decline to answer any particular question in the study. I 
consent the members of the study to have access to my response and to publish the result, 
provided my identity is not revealed. I voluntarily agree to participate in the study. 
 
 
 
               Participant signature with date 
